PDCD1 and melanoma: In the past decades, immune checkpoint inhibitor therapy targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death receptor 1 (PD-1), and programmed cell death ligand 1 (PD-L1) have resulted in impressive outcomes in patients with malignant melanoma (2).